Is Cagrilintide FDA Approved?

DrugStatusIndex provides a clear, data-driven view of the regulatory status of medications, compounds, and related products. This page explains whether Cagrilintide is FDA approved and how it is commonly categorized.

▤

Overview

Cagrilintide is an investigational long-acting amylin analog being studied for obesity and metabolic disease treatment. It is commonly discussed alongside semaglutide in combination therapy research.

FDA Status Details

Cagrilintide is classified as Not FDA Approved. It remains in clinical development and has not received FDA approval for prescription use or commercial treatment.

Clinical Trial Status

Cagrilintide is currently associated with clinical trials and investigational use only. It does not have an FDA-approved branded prescription version available in the United States.

⚗

Combination Therapy Interest

Cagrilintide is often referenced with semaglutide in the investigational combination known as CagriSema. Neither Cagrilintide alone nor the combination therapy currently has standalone FDA approval.

Cagrilintide FDA Status

Not FDA Approved

Cagrilintide is listed as Not FDA Approved. It is an investigational metabolic therapy and should not be represented as an approved prescription medication.

Why People Search This

Users often search for Cagrilintide to understand whether it is approved for weight loss, how it compares to GLP-1 medications, and whether CagriSema is already available by prescription.

Disclaimer

This page is for informational purposes only and reflects publicly available regulatory data. It does not provide medical advice or treatment recommendations.

Search Another Drug or Compound

Use DrugStatusIndex to review public regulatory status information for medications, compounds, and related products.

Search the Index